Total operating loss from continuing operations increased from $6.6 million in 2023 to $6.9 million in 2024. Research and ...

AM-125 is a reformulation of betahistine, a histamine analog, which in the traditional oral formulation is the standard of care treatment for vertigo in many countries around the world ...

Thanks Cova. I will now discuss briefly our two main legacy assets, the Bentrio drug-free nasal spray for allergy and our AM-125 betahistine nasal spray for vertigo and other disorders of the ...

Management to host conference call today, April 30, at 8:00 a.m. EDTRNA delivery business progressing with platform development, new applications ...

Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today ...

The Board of Directors of Kirloskar Pneumatic Company Limited, at its meeting held today have approved the financial results ...